Humacyte, Inc.

HUMA Healthcare Biotechnology

Humacyte, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.0 million, up 30.2% from fiscal 2022.

Revenue
+34.9%
EPS
+33.3%
Free cash flow
+17.9%
Total debt
+437.5%

Quarter to June 2026, against a year earlier

0.44 0.04 +10.00%
Market cap
$109.9M
P/E
0.0×
Fwd P/E
−1.1×
Dividend yield
—
F-score
n/a
Altman Z
−10.48
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
ROE

+8 more TTM periods

114.92% 164.78% (399.51%) (534.42%)
ROA
(38.15%) (32.12%) (69.73%) (68.16%)
ROIC
(2,258.85%) (449.67%) (268.02%) (433.66%)
Return on Tangible Assets
(110.43%) (60.08%) (146.96%) (100.37%)
Average Days of Receivables
250.46 78.98 78.58 56.79
Free Cash Flow per Share
(0.67) (0.67) (0.52) (0.42)
Free Cash Flow
(106.40) (105.93) (102.38) (97.56)
Other line items

Show all line items

Columns are period end dates